Creso first to obtain export rights for high quality medicinal cannabis from Switzerland
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma Limited (ASX:CPH) has signed a binding Letter of Intent (LOI) with Cannapharm AG to provide patients in Asia Pacific and Latin America (LATAM) access to top quality medicinal cannabis products from Switzerland.
This is a significant commercial partnership as it will give Creso a first-mover advantage in exporting best-in-class pharmaceutical-grade medicinal cannabis products into these new markets for use to address a range of serious diseases.
Both parties will work towards formalising the collaboration agreement whereby Cannapharm will grant CPH the exclusive rights to import, store, transport, market, distribute, use and sell Cannapharm’s medicinal cannabis products in seven countries in Asia Pacific and LATAM.
By way of background, Cannapharm is a Swiss-based producer of fully Good Manufacturing Practices (GMP) certified medicinal cannabis, licensed by the Swiss Agency for Therapeutic Products (Swissmedic) to manufacture and wholesale medicines.
The group has over 15 years of experience producing products that meet the highest pharmaceutical and GMP standards in the tightly regulated Swiss market, making it a valuable partner for CPH.
The agreement will incorporate distribution to Australia, New Zealand, China, Brazil, Chile, Colombia and Mexico, and also allows for both parties to expand the exclusivity to include additional countries or regions. CPH will operate in strict compliance with all applicable legislations and regulations in the relevant countries.
Builds on position in Australia while providing first mover advantage in overseas markets
This is a significant commercial partnership as it will provide Creso with a first-mover advantage and give it a level of exclusivity in exporting best-in-class pharmaceutical-grade medicinal cannabis products into these new markets for use in addressing a range of serious diseases.
It should be noted here that CPH is an early stage play and investors should seek professional financial advice if considering this stock for their portfolio.
Commenting on the significance of this development, CPH’s Chief Executive Dr. Miri Halperin Wernli said, “This partnership with Cannapharm significantly builds on our position within the Australian market as a leading medicinal cannabis company that intends to supply the Australian market with high quality medicinal cannabis products”.
Dr. Halperin Wernli highlighted the fact that Cannapharm is the perfect partner and strategic fit for Creso given the group’s expertise in the cultivation, manufacture and distribution of cannabis derived therapeutic products.
The agreement will strengthen CPH’s overall franchise in the broader cannabis space, bolstering the company’s strong position in the various applications of cannabis and hemp-derived therapeutic solutions in markets where regulations are providing commercial opportunity.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
